Over the past two decades, the role of vitreomacular adhesion in vitreomacular interface pathologies, such as vitreomacular traction syndrome, epiretinal membrane and macular hole, has been ...
The composition of vitreous is 98% water and 2% structural macromolecules. Early in embryonic development, the molecular constituents of vitreous form a clear, gel-like structure that is adherent to ...
ThromboGenics has received FDA approval for a drug to treat symptomatic vitreomacular adhesion, according to a news release. The drug, Jetrea, is approved to treat the eye condition, which can ...
ThromboGenics NV (Euronext Brussels: THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces that its partner Alcon has ...
Our news editors obtained a quote from the research from Navigant Consulting, "Medicare payment rates were applied and a national scenario analysis was conducted. With ocriplasmin available, ...
In two ancillary studies of two multi-center international clinical trials led by the University of Southern California (USC) Eye Institute, the injectable drug ocriplasmin appears to improve vision ...
Germany's IQWiG Confirms That ThromboGenics' JETREA® Demonstrates Major Added Value for the Treatment of Vitreomacular Traction and Macular Hole ThromboGenics NV (Euronext Brussels: THR) a ...
WASHINGTON (Reuters) - A Food and Drug Administration panel on Thursday recommended ThromboGenics NV's ocriplasmin as a treatment for vitreomacular adhesion, an aging-related vision problem that can ...
Leuven, March 16, 2015 - ThromboGenics NV (Euronext Brussels:THR), an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, today announces ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results